Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q86SR1
UPID:
GLT10_HUMAN
Alternative names:
Polypeptide GalNAc transferase 10; Protein-UDP acetylgalactosaminyltransferase 10; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10
Alternative UPACC:
Q86SR1; B3KXC9; Q6IN56; Q86VP8; Q8IXJ2; Q8TEJ2; Q96IV2; Q9H8E1; Q9Y4M4
Background:
Polypeptide N-acetylgalactosaminyltransferase 10, also known as Protein-UDP acetylgalactosaminyltransferase 10 or UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 10, plays a crucial role in the biosynthesis of O-linked oligosaccharides. It catalyzes the transfer of an N-acetyl-D-galactosamine residue to serine or threonine residues on protein receptors, with activity towards Muc5Ac and EA2 peptide substrates.
Therapeutic significance:
Understanding the role of Polypeptide N-acetylgalactosaminyltransferase 10 could open doors to potential therapeutic strategies.